22, December 2016

Update on Lupuzor™ Pivotal Phase III Study - Patient Recruitment Completed

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm that patient recruitment has successfully been completed, on target, within the Company’s pivotal Phase III clinical trial...

Click here for more details

16, November 2016

Update on Cancer Compound IPP-204106 ‘Nucant’

Mechanism of Action Published in Prestigious Medical Journal ‘Cancer Research’ ImmuPharma plc (LSE:IMM) ("ImmuPharma" or the "Company" or the "Group"), the specialist discovery and deve...

Click here for more details

09, November 2016

Notification of Major Interest by Legal & General

ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received notification by Legal & General Group Plc (“L&G”...

Click here for more details

26, October 2016

TR1 Notification of Major Interest

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that it has received a TR-1 by Lanstead Capital LP (“Lanstead”). Lanstead’s holding in ImmuPharma is now confirmed at a tot...

Click here for more details

21, October 2016

Close of Accelerated Bookbuild

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that further to the announcement made earlier today entitled "Proposed Accelerated Bookbuild for Vendor Placing and Issue o...

Click here for more details

21, October 2016

Proposed Accelerated Bookbuild for Vendor Placing and Issue of Equity

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce a proposed placing of 7,100,000 existing ordinary shares of 10p each (“Ordinary Shares”) held by Lanstead Capital L....

Click here for more details

30, September 2016

INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2016

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2016 (the “Perio...

Click here for more details

14, September 2016

Update on Lupuzor’s Pivotal Phase III Study - 11 US Sites Now Open, 5 European Countries Now Recruiting

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthr...

Click here for more details

07, September 2016

ImmuPharma Invited to Open an Additional Site in Mauritius

Up to 30 Lupus patients ready for enrolmentImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, it...

Click here for more details

20, June 2016

Northland Capital Appointed as Joint Broker

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces the appointment of Northland Capital Partners as joint broker to the Company, alongside...

Click here for more details

08, June 2016

Immupharma Hosts Lupuzor ™ Symposium with Lupuzor's™ Inventor, Prof. Sylviane Muller

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to confirm that today and tomorrow, 8 & 9 June, it is hosting a number of presentations on Lupuzor™, the Company’s lead co...

Click here for more details

07, June 2016

First European Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthr...

Click here for more details

31, May 2016

Notification of Major Interest by Alto Invest to 4.15%

ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that on 30 May 2016 it received notification by Alto Invest and its subsidiaries (“...

Click here for more details

25, May 2016

Notification of Major Interest by Alto Invest

ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that on 24 May 2016 it received notification by Alto Invest and its subsidiaries (“...

Click here for more details

04, May 2016

Annual Report and Accounts - Notice of Annual General Meeting: 26 May 2016

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company confirms that the Annual Report and Accounts for the year ended 31 December 2015 has been posted to...

Click here for more details

04, May 2016

PRELIMINARY RESULTS
 for the year ended 31 December 2015

ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce its preliminary  results for the year ended 31 December 2015.Key Highli...

Click here for more details

26, April 2016

Notification of Preliminary Results. Date: 4 May 2016

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company confirms that it will announce its Preliminary results for the year ended 31 December 2015 on Wedne...

Click here for more details

10, March 2016

First European site opened in France and Patient Recruitment Commences in Lupuzor's™ Pivotal Phase III Study

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its pivotal Phase III clinical trial of...

Click here for more details

01, March 2016

Confirmation of EIS and VCT Qualifying Status and Issue of Equity. £8.4 million total proceeds raised by ImmuPharma within the recent Placing and Subscription

ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received advance assurance from HM Revenue and Customs that it is a qualifyin...

Click here for more details

23, February 2016

Result of GM

ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce that at its General Meeting today, held in connection with the Placing and S...

Click here for more details

15, February 2016

First US Patients Commence Dosing in Lupuzor's™ Pivotal Phase III Study 

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor&...

Click here for more details

05, February 2016

Placing and Subscription Raises £8.3 million

ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce the successful completion of the conditional fund raise, comprising the Plac...

Click here for more details

05, February 2016

Proposed Placing and Subscription and Notice of General Meeting: 22 February 2016

ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce a proposed conditional fund raise of not less than £7.5 million. This...

Click here for more details